The following amendment has been made to the 'Issue of Shares' announcement released on 17 July 2023 at 07:00 under RNS No 1495G

The correct figure for the principal remaining under the convertible bond after the settlement of the repayment is $15.90 million.

All other details remain unchanged.

The full amended text is shown below.

Renalytix plc

("Renalytix" or the "Company")

Issue of Shares

LONDON and SALT LAKE CITY - July 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the Company's convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 526,211 American Depositary Shares ("ADS").

After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $15.90 million.

1,052,422 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") will be issued to settle the conversion of 526,211 ADSs, with each ADS representing two Ordinary Shares.

An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 1,052,422 new Ordinary Shares to trading on AIM will become effective on, or around, 8am UK time on 19 July 2023 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

Total voting rights

Following Admission, the Company will have 94,833,900 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 94,833,900.

For further information, please contact:

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.